海正藥業(600267.SH):資產重組方案調整獲浙江省國資委批覆
格隆匯12月4日丨海正藥業(600267.SH)公佈,2020年12月4日,公司收到浙江省國資委下發的《浙江省國資委關於同意調整浙江海正藥業股份有限公司發行股份、可轉換公司債券及支付現金購買資產並募集資金方案的批覆》,主要內容如下:
一、原則同意浙江海正藥業股份有限公司調整後的發行股份、可轉換公司債券及支付現金購買資產並募集資金方案。
二、同意浙江海正藥業股份有限公司向HPPC Holding SARL發行股份1.43億股、發行面值100元可轉換公司債券1815.24萬張及支付現金購買HPPC Holding SARL持有的瀚暉製藥有限公司49%股權;向台州市椒江區國有資本運營集團有限公司發行股份不超過5993.15萬股股份,募集配套資金不超過7億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.